Cargando…

2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022

BACKGROUND: Reports have shown increases in carbapenem-resistant Acinetobacter baumannii complex (CRAB) infections during the COVID-19 pandemic. To describe the effect of SARS-CoV-2 (SC2) infection on CRAB infection epidemiology, we analyzed data from the Centers for Disease Control and Prevention’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulens, Sandra N, Hall, Amanda, Jacob, Jesse T, Smith, Gillian, Wilson, Lucy E, Vaeth, Elisabeth, Wilson, Christopher, Muleta, Daniel, Dumyati, Ghinwa, Tsay, Rebecca, Maloney, Meghan, Stabach, Nicole, Lynfield, Ruth, O’Malley, Sean, Pierce, Rebecca, Hertzel, Heather, Czaja, Christopher A, Johnston, Helen, Grass, Julian E, Brandenburg, Joshua, Guh, Alice, Magill, Shelley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677360/
http://dx.doi.org/10.1093/ofid/ofad500.2076
_version_ 1785150111337152512
author Bulens, Sandra N
Hall, Amanda
Jacob, Jesse T
Smith, Gillian
Wilson, Lucy E
Vaeth, Elisabeth
Wilson, Christopher
Muleta, Daniel
Dumyati, Ghinwa
Tsay, Rebecca
Maloney, Meghan
Stabach, Nicole
Lynfield, Ruth
O’Malley, Sean
Pierce, Rebecca
Hertzel, Heather
Czaja, Christopher A
Johnston, Helen
Grass, Julian E
Brandenburg, Joshua
Guh, Alice
Magill, Shelley
author_facet Bulens, Sandra N
Hall, Amanda
Jacob, Jesse T
Smith, Gillian
Wilson, Lucy E
Vaeth, Elisabeth
Wilson, Christopher
Muleta, Daniel
Dumyati, Ghinwa
Tsay, Rebecca
Maloney, Meghan
Stabach, Nicole
Lynfield, Ruth
O’Malley, Sean
Pierce, Rebecca
Hertzel, Heather
Czaja, Christopher A
Johnston, Helen
Grass, Julian E
Brandenburg, Joshua
Guh, Alice
Magill, Shelley
author_sort Bulens, Sandra N
collection PubMed
description BACKGROUND: Reports have shown increases in carbapenem-resistant Acinetobacter baumannii complex (CRAB) infections during the COVID-19 pandemic. To describe the effect of SARS-CoV-2 (SC2) infection on CRAB infection epidemiology, we analyzed data from the Centers for Disease Control and Prevention’s Emerging Infections Program (EIP) population-based CRAB surveillance in 9 U.S. sites. [Figure: see text] Methods: In 2020–22, among surveillance-area residents, an incident CRAB case was defined as the 1(st) isolation of A. baumannii complex resistant to ≥1 carbapenem (excluding ertapenem) from a normally sterile site or urine (or lower respiratory tract or wound, as of 2021) in a 30-day period. We included cases that underwent chart review. Cases with a culture collected ≥3 days after hospitalization were considered hospital-onset (HO); all others were community-onset (CO). Cases with a SC2+ test ≤14 days before the incident CRAB culture were compared to other CRAB cases. RESULTS: Of 406 CRAB cases representing 344 patients, 26 (6%) cases in 24 patients were SC2+. SC2+ case-patients were more likely to be female than other CRAB case-patients (58% vs 34%, p=0.02); there were no significant differences in race/ethnicity or age distribution. SC2+ cases were more likely to be obese (42% vs. 23%, p=0.03), have bacteremia (23% vs. 10%, p=0.05), and to have died (39% vs. 16%, p=0.003). SC2+ cases were also more likely to require hospitalization (100% vs. 75%, p=0.005) and have HO CRAB (58% vs 29%, p=0.003). Median hospital length of stay was longer in SC2+ cases (19 days, interquartile range [IQR] 8–30) than in other CRAB cases (14 days, IQR 7–26, p=0.42), but there were no significant differences in the percentages with intensive care unit stays or mechanical ventilation in the 7 days before CRAB culture. Culture sources and infection types in SC2+ cases vs. other CRAB cases are shown in the Table. CONCLUSION: A small minority of CRAB patients were infected with SC2+ in the 14 days before CRAB infection but these patients had epidemiological and clinical features that were distinct from other CRAB patients, including higher mortality. Infection control and clinical measures are needed to protect SC2+ patients from secondary bacterial infection and mitigate poor outcomes in those with SC2 and CRAB infection. DISCLOSURES: Ghinwa Dumyati, MD, Pfizer: Grant/Research Support Rebecca Tsay, MPH, CDC: Grant/Research Support
format Online
Article
Text
id pubmed-10677360
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106773602023-11-27 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022 Bulens, Sandra N Hall, Amanda Jacob, Jesse T Smith, Gillian Wilson, Lucy E Vaeth, Elisabeth Wilson, Christopher Muleta, Daniel Dumyati, Ghinwa Tsay, Rebecca Maloney, Meghan Stabach, Nicole Lynfield, Ruth O’Malley, Sean Pierce, Rebecca Hertzel, Heather Czaja, Christopher A Johnston, Helen Grass, Julian E Brandenburg, Joshua Guh, Alice Magill, Shelley Open Forum Infect Dis Abstract BACKGROUND: Reports have shown increases in carbapenem-resistant Acinetobacter baumannii complex (CRAB) infections during the COVID-19 pandemic. To describe the effect of SARS-CoV-2 (SC2) infection on CRAB infection epidemiology, we analyzed data from the Centers for Disease Control and Prevention’s Emerging Infections Program (EIP) population-based CRAB surveillance in 9 U.S. sites. [Figure: see text] Methods: In 2020–22, among surveillance-area residents, an incident CRAB case was defined as the 1(st) isolation of A. baumannii complex resistant to ≥1 carbapenem (excluding ertapenem) from a normally sterile site or urine (or lower respiratory tract or wound, as of 2021) in a 30-day period. We included cases that underwent chart review. Cases with a culture collected ≥3 days after hospitalization were considered hospital-onset (HO); all others were community-onset (CO). Cases with a SC2+ test ≤14 days before the incident CRAB culture were compared to other CRAB cases. RESULTS: Of 406 CRAB cases representing 344 patients, 26 (6%) cases in 24 patients were SC2+. SC2+ case-patients were more likely to be female than other CRAB case-patients (58% vs 34%, p=0.02); there were no significant differences in race/ethnicity or age distribution. SC2+ cases were more likely to be obese (42% vs. 23%, p=0.03), have bacteremia (23% vs. 10%, p=0.05), and to have died (39% vs. 16%, p=0.003). SC2+ cases were also more likely to require hospitalization (100% vs. 75%, p=0.005) and have HO CRAB (58% vs 29%, p=0.003). Median hospital length of stay was longer in SC2+ cases (19 days, interquartile range [IQR] 8–30) than in other CRAB cases (14 days, IQR 7–26, p=0.42), but there were no significant differences in the percentages with intensive care unit stays or mechanical ventilation in the 7 days before CRAB culture. Culture sources and infection types in SC2+ cases vs. other CRAB cases are shown in the Table. CONCLUSION: A small minority of CRAB patients were infected with SC2+ in the 14 days before CRAB infection but these patients had epidemiological and clinical features that were distinct from other CRAB patients, including higher mortality. Infection control and clinical measures are needed to protect SC2+ patients from secondary bacterial infection and mitigate poor outcomes in those with SC2 and CRAB infection. DISCLOSURES: Ghinwa Dumyati, MD, Pfizer: Grant/Research Support Rebecca Tsay, MPH, CDC: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10677360/ http://dx.doi.org/10.1093/ofid/ofad500.2076 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Bulens, Sandra N
Hall, Amanda
Jacob, Jesse T
Smith, Gillian
Wilson, Lucy E
Vaeth, Elisabeth
Wilson, Christopher
Muleta, Daniel
Dumyati, Ghinwa
Tsay, Rebecca
Maloney, Meghan
Stabach, Nicole
Lynfield, Ruth
O’Malley, Sean
Pierce, Rebecca
Hertzel, Heather
Czaja, Christopher A
Johnston, Helen
Grass, Julian E
Brandenburg, Joshua
Guh, Alice
Magill, Shelley
2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022
title 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022
title_full 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022
title_fullStr 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022
title_full_unstemmed 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022
title_short 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022
title_sort 2458. carbapenem-resistant acinetobacter baumannii complex infections and sars-cov-2 positivity in 9 u.s. sites, 2020-2022
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677360/
http://dx.doi.org/10.1093/ofid/ofad500.2076
work_keys_str_mv AT bulenssandran 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT hallamanda 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT jacobjesset 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT smithgillian 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT wilsonlucye 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT vaethelisabeth 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT wilsonchristopher 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT muletadaniel 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT dumyatighinwa 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT tsayrebecca 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT maloneymeghan 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT stabachnicole 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT lynfieldruth 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT omalleysean 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT piercerebecca 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT hertzelheather 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT czajachristophera 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT johnstonhelen 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT grassjuliane 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT brandenburgjoshua 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT guhalice 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022
AT magillshelley 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022